Press Release | Apr 06, 2016

Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of new clinical study results supporting the bioavailability of Nitrosigine® bonded arginine silicate (ASI), titled, “A Pharmacokinetic Evaluation of the Duration of Effect of Inositol-Stabilized Arginine Silicate and Arginine Hydrochloride in Healthy Adult Males.” The study was presented on April 3rd, 2016 to scientists

News | Oct 22, 2015

JDS Therapeutics, LLC, a privately held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a $16 million Series B institutional equity financing round led by 1315 Capital, a Philadelphia-based investment firm specializing in healthcare.

News | May 18, 2015

Encore Dermatology, Inc. announced today that it has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals. In addition to the founders, principal investors will be Essex Woodlands, 1315 Capital and Longitude Capital.

News | May 01, 2014

Adele Oliva shares how she chooses companies to invest in with Arianne Cohen from Bloomberg: “I look for great teams, because they can create outstanding returns as well as save your bacon in tough situations, particularly in the growth stage, where I focus. In health care, we live and die by management’s experience and ability

Pages 1 12 13 14 15